MLL-r
Showing 1 - 25 of 2,877
Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Mixed Phenotype Acute Leukemia
Not yet recruiting
- Recurrent Acute Leukemia of Ambiguous Lineage
- +5 more
- Biospecimen Collection
- +12 more
- (no location specified)
Mar 8, 2023
Acute Lymphoblastic Leukemia, Acute Undifferentiated Leukemia, Childhood T Acute Lymphoblastic Leukemia Trial in Worldwide
Active, not recruiting
- Acute Lymphoblastic Leukemia
- +2 more
- Asparaginase
- +17 more
-
Birmingham, Alabama
- +169 more
Aug 17, 2022
Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute Trial in Japan, United States (DSP-5336)
Recruiting
- Leukemia, Myeloid, Acute
- Leukemia, Lymphocytic, Acute
-
Houston, Texas
- +5 more
May 31, 2022
Better Leukemia Diagnostics Through AI (BELUGA)
Recruiting
- Hematologic Malignancy
- +4 more
- Automated AI-Guided Diagnosis of Hematological Malignancies
-
Munich, Bavaria, GermanyMLL Munich Leukemia Laboratory
Apr 4, 2022
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Mixed-Phenotype Leukemia Trial in United States (BMF-500)
Not yet recruiting
- Acute Myeloid Leukemia
- +2 more
-
Los Angeles, California
- +9 more
Jun 27, 2023
Acute Myeloid Leukemia Trial in Kunming (CLL1 and CD38 dual-target CAR-T injection)
Recruiting
- Acute Myeloid Leukemia
- CLL1 and CD38 dual-target CAR-T injection
-
Kunming, Yunnan, China920th Hospital of Joint LogisticsSupport Force of People's Liber
Oct 26, 2023
DLBCL Trial in Suzhou (Chidamide, Azacitidine, obinutuzumab)
Recruiting
- Diffuse Large B-Cell Lymphoma
- Chidamide
- +3 more
-
Suzhou, Jiangsu, Chinathe First Affiliated Hospital of Soochow University
Apr 10, 2023
PD-1 Refractory Advanced Melanoma Trial in Pittsburgh (Responder-Derived Fecal microbiota transplantation (R-FMT, Pembrolizumab,
Not yet recruiting
- PD-1 Refractory Advanced Melanoma
- Responder-Derived Fecal microbiota transplantation (R-FMT
- +2 more
-
Pittsburgh, PennsylvaniaUPMC Hillman Cancer Center
Sep 1, 2023
AML, MDS Trial in Tianjin (XZB-0004)
Not yet recruiting
- AML
- MDS
-
Tianjin, Tianjin, ChinaHematology Hospital, Chinese Academy of Medical Sciences
Feb 13, 2023
Relapsed/Refractory Large B-cell Lymphoma Trial (KITE-197, Cyclophosphamide, Fludarabine)
Not yet recruiting
- Relapsed/Refractory Large B-cell Lymphoma
- KITE-197
- +2 more
- (no location specified)
Oct 6, 2023
Radiotherapy, Breast Cancer, Relaxation Trial in Munich (Respiratory training and relaxation techniques under adjuvant radiation
Recruiting
- Radiotherapy
- +3 more
- Respiratory training and relaxation techniques under adjuvant radiation therapy in DIBH in breast cancer
-
Munich, GermanyDepartment of Radiation Oncology, Technical University of Munich
Aug 1, 2023
Acute Lymphoblastic Leukemia Trial in Memphis (Prednisone, Vincristine, Daunorubicin, PEG-L-asparaginase, Erwinia
Completed
- Acute Lymphoblastic Leukemia
- Prednisone, Vincristine, Daunorubicin, PEG-L-asparaginase, Erwinia L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Thioguanine
- Clofarabine, Methotrexate, Mercaptopurine, Dexamethasone, Etoposide, Dasatinib
-
Memphis, TennesseeSt. Jude Children's Research Hospital
Jul 26, 2022
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Follicular Lymphoma Trial in Australia, China (BGB-10188,
Recruiting
- Chronic Lymphocytic Leukemia
- +9 more
- BGB-10188
- +2 more
-
Adelaide, Australia
- +12 more
Jan 6, 2023
Marginal Zone Lymphoma Trial (Mosunetuzumab + Lenalidomide, - Rituximab + Lenalidomide (28-days cycles, - Rituximab +
Not yet recruiting
- Marginal Zone Lymphoma
- Mosunetuzumab + Lenalidomide
- +3 more
- (no location specified)
Aug 16, 2023
Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma Trial in Tianjin (CD19-targeted Chimeric Antigen Receptor(CAR) T Cells)
Recruiting
- Lymphoma, Non-Hodgkin
- Diffuse Large B Cell Lymphoma
- CD19-targeted Chimeric Antigen Receptor(CAR) T Cells
-
Tianjin, Tianjin, ChinaTianjin Cancer Hospital
Nov 19, 2023
Nociception Coma Scale-Revised With Personalized Stimulus
Recruiting
- Disorder of Consciousness
- Nociception Coma Scale-Revised
-
Rome, ItalyRita Formisano
Aug 24, 2023
Relapsed/Refractory Peripheral T-cell Lymphoma, Relapsed/Refractory Classical Hodgkins Lymphoma Trial in Worldwide (AZD4573)
Recruiting
- Relapsed/Refractory Peripheral T-cell Lymphoma
- Relapsed/Refractory Classical Hodgkins Lymphoma
-
Duarte, California
- +33 more
Jan 5, 2023
Diffuse Large B-cell Lymphoma Trial (Rituximab, Mitoxantrone HCl liposome, Isophosphamide)
Not yet recruiting
- Diffuse Large B-cell Lymphoma
- Rituximab
- +7 more
- (no location specified)
Mar 23, 2023
Non-Hodgkin's Lymphoma, Relapsed, Chronic Lymphoid Leukemia in Relapse, Non-Hodgkin's Lymphoma Refractory Trial in United States
Completed
- Non-Hodgkin's Lymphoma, Relapsed
- +8 more
- PBCAR20A
- +2 more
-
Duarte, California
- +4 more
Jan 4, 2023
Relmacabtagene Autoleucel in Patients With LBCL
Recruiting
- Large B-cell Lymphoma
- Relmacabtagene Autoleucel
-
Shanghai, Shanghai, ChinaRuijin Hospital Affiliated to Shanghai Jiao Tong University Scho
Nov 15, 2023
B-Cell Lymphoma, Non-Hodgkin Lymphoma Trial in Worldwide (Glofitamab, Obinutuzumab (G), Rituximab (R))
Active, not recruiting
- B-Cell Lymphoma
- Non-Hodgkin Lymphoma
- Glofitamab
- +8 more
-
Birmingham, Alabama
- +23 more
Dec 2, 2022